Results 221 to 230 of about 5,292 (260)
Some of the next articles are maybe not open access.
Chest, 2004
Tiotropium bromide is a novel, inhaled, once-daily anticholinergic bronchodilator that has recently been approved in the United States for use in patients with COPD. Its unique feature is the persistence of bronchodilation for > 24 h due to prolonged M(3) muscarinic receptor blockade.
Gillian M. Keating, Susan J Keam
+7 more sources
Tiotropium bromide is a novel, inhaled, once-daily anticholinergic bronchodilator that has recently been approved in the United States for use in patients with COPD. Its unique feature is the persistence of bronchodilation for > 24 h due to prolonged M(3) muscarinic receptor blockade.
Gillian M. Keating, Susan J Keam
+7 more sources
Olodaterol + tiotropium bromide for the treatment of COPD
Expert Review of Respiratory Medicine, 2016Patients suffering from COPD not controlled by a single bronchodilator should be given two bronchodilators with different mechanisms of action. Addition of a LABA to a LAMA induces a larger bronchodilation than that obtained with the LAMA as monotherapy and also improves many patient-reported outcomes.
Calzetta L. +3 more
openaire +5 more sources
Safety and pharmacological profile of tiotropium bromide
Expert Opinion on Drug Safety, 2009Chronic obstructive pulmonary disease (COPD) is associated with progressive airflow obstruction and is characterized by a high risk of morbidity and mortality. With early detection and treatment, the natural history of this disease may be improved. So far, bronchodilator therapy is the most important treatment for COPD.
P. Santus, F. Di Marco
openaire +3 more sources
Tiotropium bromide for cystic fibrosis
Expert Opinion on Orphan Drugs, 2015Introduction: Airway obstruction is a common feature in cystic fibrosis (CF) patients and bronchodilators, either short or long acting, are widely used in CF care.Areas covered: Tiotropium bromide is a long-acting anticholinergic muscarinic receptor antagonist, leading to bronchodilation and to a lesser extent reduction of airway secretions.
Felix Ratjen, Saadoun Bin-Hasan
openaire +2 more sources
Tiotropium Bromide in Children and Adolescents with Asthma
Pediatric Drugs, 2017Evidence is emerging on the use of long-acting muscarinic antagonists (LAMAs) in the management of asthma. Tiotropium bromide (Spiriva® Respimat®) is the only LAMA approved in children and adolescents. As the use of tiotropium becomes more common in clinical practice, it is necessary to review the existing data to identify patients who may benefit from
H. William Kelly, Hengameh H. Raissy
openaire +3 more sources
Tiotropium bromide for chronic obstructive pulmonary disease
Expert Review of Respiratory Medicine, 2009Tiotropium bromide is a long-acting, once-daily inhaled anticholinergic approved for the treatment of chronic obstructive pulmonary disease (COPD). Functional and kinetic selectivity for muscarinic (M) receptors, M(1) and M(3), in the lung permit sustained bronchodilation in moderate and severe COPD.
Gerard J. Criner, A. James Mamary
openaire +3 more sources
Expert Opinion on Investigational Drugs, 2001
Tiotropium bromide is a new long-lasting anticholinergic drug which, like ipratropium bromide, is a quaternary ammonium derivative. It binds with high affinity to muscarinic receptors but dissociates very slowly from M(1)- and M(3)-muscarinic receptors.
openaire +2 more sources
Tiotropium bromide is a new long-lasting anticholinergic drug which, like ipratropium bromide, is a quaternary ammonium derivative. It binds with high affinity to muscarinic receptors but dissociates very slowly from M(1)- and M(3)-muscarinic receptors.
openaire +2 more sources
Olodaterol + tiotropium bromide for the treatment of chronic obstructive pulmonary disease
Expert Review of Clinical Pharmacology, 2015A solid scientific rationale and an increasing body of clinical evidence for combining a β2-agonist with an antimuscarinic agent in COPD fully support the opinion that patients not controlled by a single bronchodilator should be given two bronchodilators with different mechanisms of action.
CAZZOLA, MARIO +3 more
openaire +5 more sources
Effect of tiotropium bromide on airway remodeling in a chronic asthma model
Annals of Allergy, Asthma & Immunology, 2012Recent evidence suggests that acetylcholine acting through muscarinic receptors may play an inhibitory role in the mechanisms that drive the structural changes in the airways called airway remodeling. The novel anticholinergic drug tiotropium bromide, which selectively antagonizes muscarinic receptors, especially the M3 subtype, and is long acting ...
Chan Kwon Park +9 more
openaire +3 more sources
Tiotropium bromide as add-on therapy to inhaled corticosteroids for treating asthma
Expert Opinion on Pharmacotherapy, 2015Bronchial asthma is becoming increasingly prevalent worldwide. Although first-line therapy with inhaled corticosteroids (ICS) with or without long-acting β2 agonists (LABA) has significantly improved the clinical outcomes of asthma, they cannot provide all asthmatics with good control and thus alternatives or add-on drugs are required.
Hiroto Matsuse +6 more
openaire +2 more sources